Vascular and oncological interventional radiology department, Georges Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris, 20 Rue Leblanc, 75015, Paris, France; Université Paris Cité, Faculté de Santé, Paris, France.
Vascular and oncological interventional radiology department, Georges Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris, 20 Rue Leblanc, 75015, Paris, France; Université Paris Cité, Faculté de Santé, Paris, France; PARCC U 970, INSERM, Paris, France.
Acad Radiol. 2024 May;31(5):1959-1967. doi: 10.1016/j.acra.2023.10.005. Epub 2023 Nov 23.
The long-term effectiveness of prostatic artery embolization (PAE) can be hampered by the recanalization of the previously embolized prostatic arteries (PA). The use of a liquid embolic agent (LEA) could limit this risk. The purpose of this study was to assess the safety and efficacy of repeat PAE (rePAE) using a LEA (Squid Peri) coupled with microspheres in patients experiencing recurring symptoms after initial embolization.
This retrospective single-center study included all consecutive patients who underwent rePAE using Squid Peri coupled with microspheres. Angiographic patterns of prostatic revascularization were identified. Outcomes were assessed at the 3-month follow-up using the International Prostate Symptom Score (IPSS) and the Quality of Life (QoL) score. The primary endpoint was clinical success defined as an IPSS < 18 with > 25% decrease and a QoL score ≤ 3 with ≥ 1 point decrease. Safety was assessed by using the modified Clavien-Dindo classification.
30 consecutive men (mean age: 67.1 ± 9.5 years) were included. Recanalization of the previously embolized PA was found in 83.3% of patients. Technical success was 93.3%. Median follow-up was 4.9 months [IQR: 3.9 - 9.8]. Clinical success rate was 76.7%, with a mean decrease in IPSS of -9.3 ± 7.3 (p < 0.001) and a median decrease in QoL of -2 [IQR: - 4 - - 1] (p < 0.001). One patient presented with an acute urinary retention requiring readmission (grade IIIa complication).
Repeat PAE using Squid Peri coupled with microspheres is safe and effective for patients with recurring symptoms after initial embolization.
前列腺动脉栓塞术(PAE)的长期疗效可能会因先前栓塞的前列腺动脉(PA)再通而受到阻碍。使用液体栓塞剂(LEA)可能会降低这种风险。本研究旨在评估在初始栓塞后出现复发症状的患者中,使用 Squid Peri 联合微球进行重复 PAE(rePAE)的安全性和疗效。
本回顾性单中心研究纳入了所有接受 Squid Peri 联合微球进行 rePAE 的连续患者。确定了前列腺再血管化的血管造影模式。使用国际前列腺症状评分(IPSS)和生活质量(QoL)评分在 3 个月的随访时评估结局。主要终点是临床成功率定义为 IPSS < 18,下降> 25%,QoL 评分≤ 3,下降≥ 1 分。通过使用改良的 Clavien-Dindo 分类评估安全性。
共纳入 30 例连续男性(平均年龄:67.1 ± 9.5 岁)。83.3%的患者发现先前栓塞的 PA 再通。技术成功率为 93.3%。中位随访时间为 4.9 个月[IQR:3.9-9.8]。临床成功率为 76.7%,IPSS 平均下降 9.3 ± 7.3(p < 0.001),QoL 中位数下降 2 [IQR:-4 至-1](p < 0.001)。1 例患者出现急性尿潴留需要再次入院(IIIa 级并发症)。
对于初始栓塞后出现复发症状的患者,使用 Squid Peri 联合微球进行重复 PAE 是安全有效的。